154 related articles for article (PubMed ID: 24358041)
1. Consensus interferon plus ribavirin for hepatitis C genotype 3 patients previously treated with pegylated interferon plus ribavirin.
Abbas Z; Tayyab GN; Qureshi M; Memon MS; Subhan A; Shakir T; Jafri W; Hamid S
Hepat Mon; 2013; 13(12):e14146. PubMed ID: 24358041
[TBL] [Abstract][Full Text] [Related]
2. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
[TBL] [Abstract][Full Text] [Related]
3. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
Asselah T; Hézode C; Qaqish RB; ElKhashab M; Hassanein T; Papatheodoridis G; Feld JJ; Moreno C; Zeuzem S; Ferenci P; Yu Y; Redman R; Pilot-Matias T; Mobashery N
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):25-35. PubMed ID: 28404108
[TBL] [Abstract][Full Text] [Related]
4. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.
Cornberg M; Hadem J; Herrmann E; Schuppert F; Schmidt HH; Reiser M; Marschal O; Steffen M; Manns MP; Wedemeyer H
J Hepatol; 2006 Feb; 44(2):291-301. PubMed ID: 16360972
[TBL] [Abstract][Full Text] [Related]
5. Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.
Yoshida EM; Sherman M; Bain VG; Cooper CL; Deschênes M; Marotta PJ; Lee SS; Krajden M; Witt-Sullivan H; Bailey RJ; Usaty C; Peltekian K;
Can J Gastroenterol; 2009 Mar; 23(3):180-4. PubMed ID: 19319382
[TBL] [Abstract][Full Text] [Related]
6. Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.
Yee HS; Currie SL; Tortorice K; Cozen M; Shen H; Chapman S; Cunningham F; Monto A
Dig Dis Sci; 2011 Aug; 56(8):2439-48. PubMed ID: 21633833
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
8. Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial.
Alaimo G; Di Marco V; Ferraro D; Di Stefano R; Porrovecchio S; D'Angelo F; Calvaruso V; Craxì A; Almasio PL
World J Gastroenterol; 2006 Nov; 12(42):6861-4. PubMed ID: 17106937
[TBL] [Abstract][Full Text] [Related]
9. Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.
Sharvadze LG; Gogichaishvili ShSh; Sakandelidze TsG; Zhamutashvili MT; Chkhartishvili NI
Georgian Med News; 2009 Jan; (166):61-4. PubMed ID: 19202222
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
11. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
Gonçales FL; Moma CA; Vigani AG; Angerami AF; Gonçales ES; Tozzo R; Pavan MH; Gonçales NS
BMC Infect Dis; 2010 Jul; 10():212. PubMed ID: 20646277
[TBL] [Abstract][Full Text] [Related]
12. Effect of pegylated interferon on non-responders and relapsers with interferon.
Akbar HO; Al Ahwal MS
J Sci Res Med Sci; 2002 Apr; 4(1-2):9-13. PubMed ID: 24019720
[TBL] [Abstract][Full Text] [Related]
13. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Hézode C; Asselah T; Reddy KR; Hassanein T; Berenguer M; Fleischer-Stepniewska K; Marcellin P; Hall C; Schnell G; Pilot-Matias T; Mobashery N; Redman R; Vilchez RA; Pol S
Lancet; 2015 Jun; 385(9986):2502-9. PubMed ID: 25837829
[TBL] [Abstract][Full Text] [Related]
14. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non-responders and relapsers.
Abbas Z; Raza S; Hamid S; Jafri W
J Pak Med Assoc; 2012 Apr; 62(4):338-43. PubMed ID: 22755276
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS;
Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661
[TBL] [Abstract][Full Text] [Related]
18. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
Keeffe EB; Hollinger FB
Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
Younossi ZM; McCullough AC; Barnes DS; Post A; Ong JP; O'Shea R; Martin LM; Bringman D; Farmer D; Levinthal G; Mullen KD; Carey WD; Tavill AS; Ferguson R; Gramlich T
Dig Dis Sci; 2005 May; 50(5):970-5. PubMed ID: 15906777
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin.
Deltenre P; Corouge M; Canva V; Castel H; Wartel F; Dharancy S; Louvet A; Lazrek M; Moreno C; Henrion J; Mathurin P
J Hepatol; 2011 Nov; 55(5):989-95. PubMed ID: 21354445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
